Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Apellis Pharmaceuticals, Inc. - Common Stock (NQ:APLS)

24.78 -0.38 (-1.51%)
Streaming Delayed Price Updated: 1:24 PM EST, Dec 26, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Apellis Pharmaceuticals, Inc. - Common Stock

< Previous 1 2
...
13 14 15 16 17 18 19 20 Next >
News headline image
41 Stocks Moving In Friday's Mid-Day Session ↗
Gainers IVERIC bio, Inc. (NASDAQ: ISEE) shares climbed 64.4% to $14.29 after Apellis Pharmaceuticals reported results from its Phase 3 DERBY and OAKS studies in geographic... 
Via Benzinga
News headline image
Here's Why Iveric Bio Stock Is Rocketing Higher Today ↗
Mixed results from Apellis Pharmaceuticals are good news for Iveric Bio's geographic atrophy program. 
Via The Motley Fool
News headline image
ISEE Stock: Why Rival Eye Drug Developer’s Disappointment Is a Boon to IVERIC bio ↗
IVERIC bio (ISEE) stock is rocketing higher on Friday and there's a couple of catalysts behind the shares' positive movement today. 
Via InvestorPlace
News headline image
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight ↗
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in,... 
Via Benzinga
Analyst Ratings For Apellis Pharmaceuticals ↗
Within the last quarter, Apellis Pharmaceuticals (NASDAQ:APLS... 
Via Benzinga
News headline image
Here's Why Apellis Pharmaceuticals Is Getting Hammered Today ↗
Conflicting clinical trial results for the company's lead candidate are to blame. 
Via The Motley Fool
News headline image
Why IVERIC Bio Shares Are Soaring Today ↗
IVERIC Bio Inc (NASDAQ: ISEE) is trading significantly higher Friday after Apellis Pharmaceuticals Inc (NASDAQ: APLS) reported results from its Phase 3 DERBY and OAKS studies... 
Via Benzinga
News headline image
Mid-Morning Market Update: Markets Mixed; Kroger Tops Q2 Views ↗
Following the market opening Friday, the Dow traded down 0.15% to 34,827.04 while the NASDAQ rose 0.32% to 15,296.61. The S&P also rose, gaining 0.03% to 4,494.53. The U.S.... 
Via Benzinga
Topics Stocks
News headline image
Apellis Loses A Third Of Its Value; Are Its Mixed Results Enough To Win FDA OK? ↗
Apellis Pharmaceuticals reported mixed results for an eye-disease treatment, leading APLS stock to crash on Friday. 
Via Investor's Business Daily
News headline image
10 Biggest Price Target Changes For Friday ↗
Wells Fargo lowered the price target on General Motors Company (NYSE: 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For September 10, 2021 ↗
Upgrades According to JonesTrading, the prior rating for Orchid Island Capital Inc (NYSE: 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
Gainers IVERIC bio (NASDAQ:ISEE) stock increased by 65.36% to $14.37 during Friday's pre-market session. The company's market cap stands at $1.4 billion. T2... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Apellis Sinks On Data, Endo Shines On Opioid Litigation Settlement, T2 Biosystems Soars On Mutant Detection Ability of COVID Test ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 9) Adagio Therapeutics, Inc. (... 
Via Benzinga
News headline image
20 Stocks Moving in Friday's Pre-Market Session ↗
Gainers IVERIC bio, Inc. (NASDAQ: ISEE) rose 29.6% to $11.26 in pre-market trading. Iveric Bio recently reported inducement grants under Nasdaq Listing Rule 5635(c)(4). T2... 
Via Benzinga
News headline image
Apellis Unveils Mixed Results For Eye Disorder Drug, But Still Hopes To Pass FDA Finish Line ↗
Apellis Pharmaceuticals Inc's (NASDAQ: APLS) pegcetacoplan posted mixed results in two Phase 3 trials in 1,258 geographic atrophy (GA). Despite the mixed... 
Via Benzinga
News headline image
Where Apellis Pharmaceuticals Stands With Analysts ↗
Analysts have provided the following ratings for Apellis Pharmaceuticals (NASDAQ: 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For August 19, 2021 ↗
Upgrades According to DA Davidson, the prior rating for PaySign Inc (NASDAQ: 
Via Benzinga
News headline image
Recap: Apellis Pharmaceuticals Q2 Earnings ↗
Shares of Apellis Pharmaceuticals (NASDAQ:APLS) fell in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share decreased 73.25% year... 
Via Benzinga
News headline image
Unusual Options Activity Insight: Apellis Pharmaceuticals ↗
Shares of Apellis Pharmaceuticals (NASDAQ:APLS) saw some unusual options activity on Thursday. Following the unusual option alert, the stock price moved down to $65.4. Sentiment... 
Via Benzinga
News headline image
10 Biggest Price Target Changes For Thursday ↗
DA Davidson lowered the price target for WD-40 Company (NASDAQ: 
Via Benzinga
10 Biggest Price Target Changes For Friday ↗
Credit Suisse raised the price target for Capital One Financial Corporation (NYSE: 
Via Benzinga
News headline image
The Daily Biotech Pulse: Iterum's Regulatory Setback, Decision Day For Provention Bio, Cidara & Outset Medical Announce CFO Departures ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 1) Alexion Pharmaceuticals, Inc... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Spero Spikes On Pfizer Investment, FDA Nod For Jazz, Orchard Signs Licensing Deal, Acumen Pharma Debuts ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 30) Ambrx Biopharma Inc. (NYSE... 
Via Benzinga
News headline image
Apellis, Beam Ink $75M Deal To Test Base Gene Editing Against Complement Disorders ↗
Beam Therapeutics Inc (NASDAQ: BEAM) joins forces with Apellis Pharmaceuticals Inc (NASDAQ: APLS) to create new gene-editing treatments for complement-driven... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Regeneron COVID-19 Antibody Cocktail Data, FDA Nod For Mallinckrodt, Molecular Partners IPO ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 15) Apellis Pharmaceuticals,... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Roche Gets Authorization For COVID-19 Treatment, Nods For Sanofi-Regeneron In Europe, Osmotica Divestment, 2 IPOs ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 24) AngioDynamics, Inc. (NASDAQ... 
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session ↗
Gainers RAPT Therapeutics (NASDAQ:RAPT) s... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Vertex Shelves Mid-Stage Study, Precigen & Novan Jump On Data, Hematology Conference, Janux Debuts ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 10) Alexion Pharmaceuticals,... 
Via Benzinga
News headline image
The Daily Biotech Pulse: AstraZeneca, Biogen Face Clinical Trial Disappointments, Novavax Studies Coronavirus-Flu Combo Vaccine, Decision Day For Takeda ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 14) Alkermes plc (NASDAQ: ALKS... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Lyra Gains On Positive Regulatory Outcome, FDA Nod For Pfizer's Prevnar Vaccine, Merck Inks COVID-19 Treatment Supply Deal With US ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 8) Agios Pharmaceuticals, Inc... 
Via Benzinga
< Previous 1 2
...
13 14 15 16 17 18 19 20 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.